Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 112 | 2024 | 5442 | 6.460 |
Why?
|
Carcinoma, Pancreatic Ductal | 45 | 2024 | 1755 | 4.520 |
Why?
|
Pancreatic Cyst | 18 | 2024 | 369 | 2.920 |
Why?
|
Pancreatectomy | 26 | 2022 | 824 | 2.830 |
Why?
|
Pancreaticoduodenectomy | 22 | 2024 | 516 | 2.640 |
Why?
|
Adenocarcinoma, Mucinous | 15 | 2024 | 526 | 1.840 |
Why?
|
Pancreas | 29 | 2024 | 1703 | 1.600 |
Why?
|
Pancreatitis, Acute Necrotizing | 6 | 2020 | 174 | 1.570 |
Why?
|
Neuroendocrine Tumors | 9 | 2024 | 649 | 1.530 |
Why?
|
Pancreatic Fistula | 9 | 2023 | 149 | 1.460 |
Why?
|
Pancreatitis | 18 | 2019 | 1087 | 1.280 |
Why?
|
Drainage | 6 | 2021 | 1179 | 1.180 |
Why?
|
Debridement | 4 | 2020 | 494 | 1.150 |
Why?
|
Neoadjuvant Therapy | 20 | 2024 | 2896 | 1.090 |
Why?
|
Adenocarcinoma | 26 | 2022 | 6400 | 1.050 |
Why?
|
Pancreatic Ducts | 7 | 2024 | 330 | 0.930 |
Why?
|
Hepatic Artery | 1 | 2024 | 232 | 0.830 |
Why?
|
Fluorouracil | 15 | 2023 | 1656 | 0.790 |
Why?
|
Lymph Nodes | 4 | 2024 | 3472 | 0.760 |
Why?
|
Cystadenoma, Serous | 6 | 2021 | 100 | 0.680 |
Why?
|
Pancreatitis, Chronic | 5 | 2020 | 282 | 0.630 |
Why?
|
Lymphatic Metastasis | 6 | 2024 | 2930 | 0.590 |
Why?
|
Gastrinoma | 1 | 2017 | 21 | 0.580 |
Why?
|
Carcinoma, Papillary | 5 | 2012 | 792 | 0.580 |
Why?
|
Common Bile Duct Neoplasms | 3 | 2015 | 121 | 0.560 |
Why?
|
Tumor Burden | 7 | 2018 | 1909 | 0.550 |
Why?
|
Ampulla of Vater | 3 | 2015 | 150 | 0.550 |
Why?
|
Cholecystectomy | 3 | 2015 | 409 | 0.520 |
Why?
|
Deoxycytidine | 7 | 2018 | 888 | 0.520 |
Why?
|
Survival Rate | 19 | 2024 | 12875 | 0.520 |
Why?
|
Gallbladder Neoplasms | 3 | 2012 | 191 | 0.520 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2015 | 66 | 0.500 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 5 | 2023 | 196 | 0.500 |
Why?
|
Endoscopy | 4 | 2020 | 1857 | 0.500 |
Why?
|
Common Bile Duct | 2 | 2012 | 106 | 0.480 |
Why?
|
Echinococcosis, Hepatic | 1 | 2014 | 23 | 0.480 |
Why?
|
Albendazole | 1 | 2014 | 51 | 0.470 |
Why?
|
Cystadenoma, Mucinous | 4 | 2007 | 62 | 0.430 |
Why?
|
Carcinoembryonic Antigen | 5 | 2024 | 338 | 0.430 |
Why?
|
Cyst Fluid | 5 | 2024 | 83 | 0.420 |
Why?
|
Aged | 89 | 2024 | 171520 | 0.410 |
Why?
|
Aged, 80 and over | 47 | 2024 | 59680 | 0.390 |
Why?
|
Humans | 166 | 2024 | 768451 | 0.390 |
Why?
|
Leucovorin | 8 | 2023 | 643 | 0.390 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2015 | 595 | 0.380 |
Why?
|
Precancerous Conditions | 3 | 2015 | 988 | 0.380 |
Why?
|
Middle Aged | 86 | 2024 | 223418 | 0.380 |
Why?
|
Incidental Findings | 2 | 2015 | 699 | 0.350 |
Why?
|
Male | 112 | 2024 | 364781 | 0.350 |
Why?
|
Retrospective Studies | 52 | 2024 | 81834 | 0.340 |
Why?
|
Tumor Microenvironment | 5 | 2024 | 3939 | 0.330 |
Why?
|
Postoperative Complications | 11 | 2021 | 15880 | 0.330 |
Why?
|
Prognosis | 28 | 2024 | 30028 | 0.330 |
Why?
|
Watchful Waiting | 1 | 2013 | 496 | 0.320 |
Why?
|
Surgical Stapling | 2 | 2016 | 100 | 0.320 |
Why?
|
Bile Duct Neoplasms | 4 | 2020 | 617 | 0.320 |
Why?
|
Female | 98 | 2024 | 396943 | 0.310 |
Why?
|
Pancreas, Exocrine | 1 | 2008 | 48 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 8 | 2020 | 6537 | 0.310 |
Why?
|
Practice Guidelines as Topic | 3 | 2015 | 7451 | 0.300 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2008 | 62 | 0.300 |
Why?
|
Endosonography | 6 | 2023 | 622 | 0.300 |
Why?
|
Lymphoma | 1 | 2017 | 1907 | 0.300 |
Why?
|
Neoplasm Invasiveness | 12 | 2024 | 3637 | 0.290 |
Why?
|
Tomography, Spiral Computed | 1 | 2008 | 274 | 0.280 |
Why?
|
Tomography, X-Ray Computed | 20 | 2021 | 20762 | 0.270 |
Why?
|
Digestive System Surgical Procedures | 3 | 2019 | 584 | 0.260 |
Why?
|
Catheters | 2 | 2019 | 427 | 0.250 |
Why?
|
Abdomen | 2 | 2023 | 1136 | 0.250 |
Why?
|
Pancreatic Diseases | 4 | 2016 | 353 | 0.250 |
Why?
|
Subcutaneous Fat | 1 | 2008 | 402 | 0.240 |
Why?
|
Adult | 53 | 2024 | 223542 | 0.230 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2024 | 3550 | 0.230 |
Why?
|
Gastroenterology | 1 | 2011 | 588 | 0.230 |
Why?
|
Combined Modality Therapy | 9 | 2024 | 8559 | 0.230 |
Why?
|
Prednisone | 1 | 2008 | 1568 | 0.220 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 4 | 2020 | 515 | 0.220 |
Why?
|
Cytodiagnosis | 2 | 2021 | 452 | 0.220 |
Why?
|
Macrophages | 1 | 2019 | 5797 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2023 | 11843 | 0.220 |
Why?
|
Neoplasm Staging | 15 | 2024 | 11249 | 0.220 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2024 | 323 | 0.220 |
Why?
|
Cefoxitin | 1 | 2023 | 35 | 0.220 |
Why?
|
Cholelithiasis | 2 | 2017 | 408 | 0.210 |
Why?
|
Anastomosis, Surgical | 2 | 2024 | 993 | 0.210 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2020 | 958 | 0.210 |
Why?
|
Diagnosis, Differential | 12 | 2023 | 13026 | 0.210 |
Why?
|
Cystadenoma | 4 | 2018 | 79 | 0.210 |
Why?
|
Ascitic Fluid | 3 | 2000 | 189 | 0.200 |
Why?
|
Autoimmune Diseases | 3 | 2012 | 2260 | 0.200 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2002 | 85 | 0.200 |
Why?
|
Disease-Free Survival | 7 | 2024 | 6856 | 0.200 |
Why?
|
Laparoscopy | 3 | 2012 | 2056 | 0.190 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2014 | 647 | 0.190 |
Why?
|
Follow-Up Studies | 19 | 2021 | 39430 | 0.190 |
Why?
|
General Surgery | 1 | 2012 | 1714 | 0.180 |
Why?
|
Nerve Tissue | 1 | 2021 | 78 | 0.180 |
Why?
|
Lipoma | 1 | 2003 | 296 | 0.180 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13708 | 0.170 |
Why?
|
HMGA2 Protein | 1 | 2020 | 101 | 0.170 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2024 | 1051 | 0.170 |
Why?
|
Decision Support Techniques | 3 | 2018 | 2010 | 0.170 |
Why?
|
Abdominal Pain | 3 | 2015 | 1070 | 0.170 |
Why?
|
Cholangitis | 1 | 2020 | 110 | 0.160 |
Why?
|
Anti-Inflammatory Agents | 1 | 2008 | 1816 | 0.160 |
Why?
|
Acetamides | 1 | 2020 | 260 | 0.160 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3543 | 0.160 |
Why?
|
Biliary Tract Neoplasms | 1 | 2020 | 187 | 0.150 |
Why?
|
Azepines | 1 | 2020 | 329 | 0.150 |
Why?
|
Length of Stay | 4 | 2020 | 6521 | 0.150 |
Why?
|
Hypophosphatemia | 1 | 2018 | 93 | 0.150 |
Why?
|
Lymph Node Excision | 1 | 2024 | 1276 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9425 | 0.140 |
Why?
|
Treatment Outcome | 16 | 2020 | 65409 | 0.140 |
Why?
|
Exocrine Pancreatic Insufficiency | 1 | 2018 | 84 | 0.140 |
Why?
|
Cystadenocarcinoma | 2 | 2015 | 54 | 0.140 |
Why?
|
Palliative Care | 1 | 2012 | 3644 | 0.140 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 424 | 0.140 |
Why?
|
Blood Loss, Surgical | 1 | 2021 | 643 | 0.140 |
Why?
|
Angiotensins | 1 | 2017 | 141 | 0.140 |
Why?
|
Cholecystitis | 1 | 2017 | 181 | 0.140 |
Why?
|
Accreditation | 1 | 2020 | 478 | 0.140 |
Why?
|
Bile Ducts | 1 | 2017 | 288 | 0.130 |
Why?
|
Sensitivity and Specificity | 9 | 2021 | 14728 | 0.130 |
Why?
|
Extracellular Matrix Proteins | 1 | 2020 | 835 | 0.130 |
Why?
|
History, 21st Century | 2 | 2012 | 1575 | 0.130 |
Why?
|
Gallbladder | 1 | 2017 | 308 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 459 | 0.130 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1104 | 0.120 |
Why?
|
Cholestasis, Extrahepatic | 2 | 2020 | 52 | 0.120 |
Why?
|
Wound Closure Techniques | 1 | 2016 | 88 | 0.120 |
Why?
|
Surgical Instruments | 1 | 2018 | 386 | 0.120 |
Why?
|
Travel | 1 | 2021 | 800 | 0.120 |
Why?
|
Jaundice | 1 | 2015 | 95 | 0.120 |
Why?
|
Phosphates | 1 | 2018 | 767 | 0.120 |
Why?
|
Papilloma, Intraductal | 2 | 2006 | 21 | 0.120 |
Why?
|
Intraoperative Care | 1 | 2018 | 772 | 0.120 |
Why?
|
History, 20th Century | 2 | 2012 | 2772 | 0.110 |
Why?
|
Risk Assessment | 7 | 2021 | 24311 | 0.110 |
Why?
|
Natural Language Processing | 1 | 2023 | 1197 | 0.110 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 757 | 0.110 |
Why?
|
Eyeglasses | 1 | 2015 | 138 | 0.110 |
Why?
|
Caregivers | 2 | 2023 | 2302 | 0.110 |
Why?
|
HLA Antigens | 1 | 2019 | 1338 | 0.110 |
Why?
|
Algorithms | 6 | 2023 | 14158 | 0.110 |
Why?
|
Peritoneal Neoplasms | 1 | 2000 | 715 | 0.110 |
Why?
|
Biliary Tract | 1 | 2014 | 135 | 0.110 |
Why?
|
Propensity Score | 1 | 2021 | 1971 | 0.110 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2531 | 0.110 |
Why?
|
Immunohistochemistry | 6 | 2019 | 11138 | 0.110 |
Why?
|
Ferrosoferric Oxide | 1 | 2014 | 349 | 0.100 |
Why?
|
Antibodies | 1 | 2021 | 2425 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2000 | 1092 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1112 | 0.100 |
Why?
|
Remote Consultation | 1 | 2015 | 242 | 0.100 |
Why?
|
Recurrence | 3 | 2014 | 8510 | 0.100 |
Why?
|
Prospective Studies | 10 | 2024 | 54914 | 0.100 |
Why?
|
Pylorus | 2 | 2003 | 86 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2000 | 1397 | 0.100 |
Why?
|
Risk Factors | 13 | 2023 | 74915 | 0.100 |
Why?
|
Organoplatinum Compounds | 1 | 2013 | 408 | 0.100 |
Why?
|
RNA-Binding Proteins | 1 | 2020 | 1885 | 0.090 |
Why?
|
Liver Neoplasms | 3 | 2012 | 4362 | 0.090 |
Why?
|
Mixed Tumor, Malignant | 1 | 2011 | 16 | 0.090 |
Why?
|
Biopsy | 2 | 2018 | 6816 | 0.090 |
Why?
|
Embolism, Cholesterol | 1 | 2010 | 32 | 0.090 |
Why?
|
Microscopy, Confocal | 1 | 2017 | 1977 | 0.090 |
Why?
|
Carbohydrates | 2 | 2023 | 389 | 0.090 |
Why?
|
Keratins | 2 | 2004 | 502 | 0.090 |
Why?
|
Chest Pain | 1 | 2017 | 1099 | 0.090 |
Why?
|
Quality of Life | 2 | 2023 | 13497 | 0.090 |
Why?
|
Survival Analysis | 8 | 2017 | 10125 | 0.090 |
Why?
|
Polyps | 1 | 2011 | 200 | 0.080 |
Why?
|
Cholangiocarcinoma | 1 | 2015 | 563 | 0.080 |
Why?
|
Photons | 1 | 2013 | 595 | 0.080 |
Why?
|
Video Recording | 1 | 2015 | 974 | 0.080 |
Why?
|
Camptothecin | 1 | 2013 | 594 | 0.080 |
Why?
|
Paraproteinemias | 1 | 2012 | 254 | 0.080 |
Why?
|
Predictive Value of Tests | 6 | 2017 | 15460 | 0.080 |
Why?
|
Radiotherapy Dosage | 3 | 2012 | 2925 | 0.080 |
Why?
|
Stromal Cells | 2 | 2021 | 1335 | 0.080 |
Why?
|
Sepsis | 1 | 2023 | 2602 | 0.080 |
Why?
|
Esophageal and Gastric Varices | 1 | 2011 | 212 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1766 | 0.080 |
Why?
|
Prevalence | 3 | 2015 | 15880 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2015 | 1362 | 0.080 |
Why?
|
Rare Diseases | 1 | 2014 | 630 | 0.080 |
Why?
|
Necrosis | 5 | 2008 | 1621 | 0.080 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 2009 | 138 | 0.080 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2012 | 489 | 0.080 |
Why?
|
Cohort Studies | 3 | 2020 | 41797 | 0.080 |
Why?
|
Iopamidol | 1 | 2008 | 187 | 0.080 |
Why?
|
Cytarabine | 1 | 2010 | 697 | 0.070 |
Why?
|
Hospitals, General | 2 | 2022 | 807 | 0.070 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 791 | 0.070 |
Why?
|
Phosphorylation | 1 | 2019 | 8332 | 0.070 |
Why?
|
Receptors, Notch | 1 | 2012 | 752 | 0.070 |
Why?
|
Prescriptions | 1 | 2010 | 387 | 0.070 |
Why?
|
Hepatectomy | 1 | 2011 | 588 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3412 | 0.070 |
Why?
|
Trypsinogen | 4 | 1997 | 84 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2717 | 0.070 |
Why?
|
Catheter Ablation | 2 | 2017 | 2775 | 0.070 |
Why?
|
Registries | 3 | 2018 | 8373 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2021 | 8635 | 0.070 |
Why?
|
Chromogranins | 2 | 2015 | 160 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2014 | 1539 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1884 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3727 | 0.070 |
Why?
|
Societies, Medical | 3 | 2017 | 3955 | 0.070 |
Why?
|
Adipose Tissue | 1 | 2018 | 3335 | 0.070 |
Why?
|
Smad4 Protein | 2 | 2019 | 193 | 0.070 |
Why?
|
Feasibility Studies | 3 | 2018 | 5308 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2021 | 9263 | 0.060 |
Why?
|
Gene Expression | 1 | 2019 | 7605 | 0.060 |
Why?
|
Proportional Hazards Models | 6 | 2021 | 12561 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2020 | 4340 | 0.060 |
Why?
|
Robotics | 1 | 2012 | 826 | 0.060 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 1 | 2006 | 100 | 0.060 |
Why?
|
Quality Improvement | 1 | 2020 | 3858 | 0.060 |
Why?
|
Haemophilus Vaccines | 1 | 2005 | 71 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2024 | 12774 | 0.060 |
Why?
|
Spleen | 1 | 2011 | 2298 | 0.060 |
Why?
|
United States | 8 | 2023 | 73121 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2024 | 16029 | 0.060 |
Why?
|
Health Planning Guidelines | 1 | 2005 | 151 | 0.060 |
Why?
|
Biopsy, Fine-Needle | 2 | 2011 | 1131 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9507 | 0.060 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 2179 | 0.060 |
Why?
|
Program Development | 1 | 2011 | 1296 | 0.060 |
Why?
|
Intraoperative Period | 2 | 2017 | 513 | 0.060 |
Why?
|
Tetanus Toxoid | 1 | 2005 | 189 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 6 | 2021 | 36840 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 18048 | 0.060 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2010 | 1680 | 0.060 |
Why?
|
Mucins | 1 | 2007 | 570 | 0.060 |
Why?
|
MicroRNAs | 1 | 2020 | 3805 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6657 | 0.060 |
Why?
|
Disease Progression | 5 | 2022 | 13655 | 0.060 |
Why?
|
SEER Program | 2 | 2020 | 1476 | 0.060 |
Why?
|
Young Adult | 9 | 2017 | 60045 | 0.060 |
Why?
|
Oligopeptides | 4 | 1999 | 1193 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5510 | 0.050 |
Why?
|
Piperacillin | 1 | 2023 | 37 | 0.050 |
Why?
|
Carcinoma, Islet Cell | 1 | 2003 | 21 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2009 | 3438 | 0.050 |
Why?
|
International Cooperation | 2 | 2020 | 1439 | 0.050 |
Why?
|
Rectal Neoplasms | 1 | 2012 | 1179 | 0.050 |
Why?
|
Patient Readmission | 1 | 2017 | 3308 | 0.050 |
Why?
|
Suture Techniques | 1 | 2008 | 776 | 0.050 |
Why?
|
Penicillanic Acid | 1 | 2023 | 41 | 0.050 |
Why?
|
Contrast Media | 3 | 2014 | 5336 | 0.050 |
Why?
|
Epithelial Cells | 1 | 2015 | 3697 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3665 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 9 | 2002 | 8201 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2021 | 2048 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 22386 | 0.050 |
Why?
|
Preoperative Care | 2 | 2010 | 2257 | 0.050 |
Why?
|
Severity of Illness Index | 4 | 2016 | 15965 | 0.050 |
Why?
|
Genes, ras | 2 | 2014 | 666 | 0.050 |
Why?
|
Adult Children | 1 | 2022 | 104 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2622 | 0.050 |
Why?
|
Morbidity | 2 | 2017 | 1760 | 0.050 |
Why?
|
Ultrasonography | 7 | 2017 | 5995 | 0.050 |
Why?
|
Adolescent | 11 | 2023 | 89168 | 0.050 |
Why?
|
Radiography | 2 | 2010 | 6995 | 0.050 |
Why?
|
Dilatation | 1 | 2023 | 311 | 0.050 |
Why?
|
Losartan | 1 | 2023 | 263 | 0.050 |
Why?
|
Dilatation, Pathologic | 1 | 2023 | 528 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 414 | 0.050 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2007 | 811 | 0.040 |
Why?
|
L-Selectin | 1 | 2001 | 212 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2008 | 4861 | 0.040 |
Why?
|
Rats | 12 | 2002 | 23839 | 0.040 |
Why?
|
Nomograms | 1 | 2022 | 236 | 0.040 |
Why?
|
Leukocytes | 2 | 1999 | 2030 | 0.040 |
Why?
|
Neutrophils | 3 | 2002 | 3790 | 0.040 |
Why?
|
Radiopharmaceuticals | 2 | 2002 | 2731 | 0.040 |
Why?
|
Macrophage-1 Antigen | 1 | 2001 | 286 | 0.040 |
Why?
|
Incidence | 4 | 2021 | 21552 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4572 | 0.040 |
Why?
|
Peritoneal Lavage | 1 | 2000 | 31 | 0.040 |
Why?
|
Pancreaticojejunostomy | 1 | 2019 | 26 | 0.040 |
Why?
|
Consensus | 2 | 2020 | 3207 | 0.040 |
Why?
|
Time Factors | 5 | 2021 | 40271 | 0.040 |
Why?
|
Hyperplasia | 1 | 2023 | 1154 | 0.040 |
Why?
|
Keratin-20 | 1 | 1999 | 31 | 0.040 |
Why?
|
Animals | 17 | 2020 | 169418 | 0.040 |
Why?
|
9,10-Dimethyl-1,2-benzanthracene | 1 | 1999 | 58 | 0.040 |
Why?
|
Chromogranin A | 1 | 1999 | 47 | 0.040 |
Why?
|
Lithotripsy | 1 | 2020 | 141 | 0.040 |
Why?
|
Efficiency | 1 | 2022 | 477 | 0.040 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 1 | 1999 | 221 | 0.040 |
Why?
|
Chymotrypsin | 1 | 1999 | 139 | 0.040 |
Why?
|
Cystadenocarcinoma, Mucinous | 1 | 1999 | 51 | 0.040 |
Why?
|
New York | 1 | 2021 | 882 | 0.040 |
Why?
|
Pain, Intractable | 1 | 2019 | 132 | 0.040 |
Why?
|
Gastric Emptying | 1 | 2001 | 246 | 0.040 |
Why?
|
Pilot Projects | 3 | 2017 | 8730 | 0.040 |
Why?
|
Acute Disease | 7 | 2017 | 7246 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 564 | 0.040 |
Why?
|
Technetium Tc 99m Exametazime | 1 | 1998 | 61 | 0.040 |
Why?
|
Pain Measurement | 1 | 2008 | 3577 | 0.040 |
Why?
|
Calcinosis | 2 | 2020 | 1485 | 0.040 |
Why?
|
Intermediate Filament Proteins | 1 | 1999 | 263 | 0.040 |
Why?
|
Gene Frequency | 1 | 2024 | 3615 | 0.040 |
Why?
|
ras Proteins | 2 | 2014 | 1058 | 0.040 |
Why?
|
California | 1 | 2021 | 1444 | 0.040 |
Why?
|
Maryland | 1 | 2017 | 277 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2024 | 2039 | 0.030 |
Why?
|
Amylases | 2 | 1997 | 171 | 0.030 |
Why?
|
Postoperative Care | 1 | 2023 | 1481 | 0.030 |
Why?
|
Statistics, Nonparametric | 3 | 2009 | 2863 | 0.030 |
Why?
|
Edema | 2 | 1999 | 766 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10784 | 0.030 |
Why?
|
Chronic Disease | 5 | 2005 | 9382 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2016 | 70 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1839 | 0.030 |
Why?
|
Genome, Human | 1 | 2009 | 4453 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1625 | 0.030 |
Why?
|
Italy | 1 | 2017 | 853 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2010 | 3197 | 0.030 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 1014 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 2002 | 1282 | 0.030 |
Why?
|
Genetic Loci | 1 | 2024 | 2630 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2633 | 0.030 |
Why?
|
Genes, p16 | 1 | 2015 | 160 | 0.030 |
Why?
|
Radiographic Image Enhancement | 1 | 1999 | 878 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2008 | 4077 | 0.030 |
Why?
|
Ethanol | 1 | 2001 | 1334 | 0.030 |
Why?
|
Gastrectomy | 1 | 2000 | 696 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
CA-19-9 Antigen | 1 | 2014 | 107 | 0.030 |
Why?
|
Fibroblasts | 1 | 2024 | 4180 | 0.030 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2015 | 304 | 0.030 |
Why?
|
Pancreatic Pseudocyst | 3 | 2000 | 112 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2010 | 4298 | 0.030 |
Why?
|
Surgical Wound Infection | 1 | 2023 | 1544 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1395 | 0.030 |
Why?
|
Radiography, Interventional | 1 | 2001 | 1127 | 0.030 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 305 | 0.030 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2015 | 195 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2017 | 965 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 17149 | 0.030 |
Why?
|
Child | 6 | 2017 | 80863 | 0.030 |
Why?
|
Surgical Mesh | 1 | 2016 | 316 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2022 | 2433 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2017 | 603 | 0.030 |
Why?
|
Radiation Injuries | 2 | 2013 | 1205 | 0.030 |
Why?
|
Cell Communication | 1 | 2020 | 1662 | 0.030 |
Why?
|
Radiotherapy | 2 | 2013 | 1510 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3624 | 0.030 |
Why?
|
Fibrosis | 1 | 2020 | 2076 | 0.030 |
Why?
|
Patient Care Team | 1 | 2024 | 2526 | 0.030 |
Why?
|
Postoperative Period | 1 | 2017 | 1833 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 270 | 0.030 |
Why?
|
Pain | 3 | 2020 | 5096 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3611 | 0.030 |
Why?
|
Magnetite Nanoparticles | 1 | 2014 | 318 | 0.020 |
Why?
|
Medicare | 2 | 2021 | 6881 | 0.020 |
Why?
|
Heparin | 1 | 2019 | 1636 | 0.020 |
Why?
|
Massachusetts | 2 | 2017 | 8908 | 0.020 |
Why?
|
Cholecystolithiasis | 1 | 2011 | 7 | 0.020 |
Why?
|
Disease Models, Animal | 4 | 2018 | 18388 | 0.020 |
Why?
|
Collagen | 1 | 2020 | 2646 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3619 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2013 | 882 | 0.020 |
Why?
|
Cell Movement | 2 | 2020 | 5223 | 0.020 |
Why?
|
Down-Regulation | 1 | 2018 | 2944 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2024 | 3629 | 0.020 |
Why?
|
Bone Marrow | 1 | 2001 | 2929 | 0.020 |
Why?
|
Dextrans | 1 | 1993 | 574 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2012 | 551 | 0.020 |
Why?
|
Glucose | 1 | 2002 | 4355 | 0.020 |
Why?
|
Survivors | 1 | 2021 | 2381 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4534 | 0.020 |
Why?
|
Reference Standards | 1 | 2014 | 1015 | 0.020 |
Why?
|
Microspheres | 1 | 1993 | 789 | 0.020 |
Why?
|
Duodenal Neoplasms | 1 | 2010 | 114 | 0.020 |
Why?
|
Intestinal Neoplasms | 1 | 2012 | 317 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2013 | 6242 | 0.020 |
Why?
|
Equipment Design | 1 | 2017 | 3530 | 0.020 |
Why?
|
Boston | 1 | 2002 | 9361 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4931 | 0.020 |
Why?
|
Phenotype | 2 | 2019 | 16712 | 0.020 |
Why?
|
Signal Transduction | 1 | 2012 | 23638 | 0.020 |
Why?
|
Gallstones | 1 | 2011 | 285 | 0.020 |
Why?
|
Failure to Thrive | 1 | 2009 | 140 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3546 | 0.020 |
Why?
|
Body Composition | 1 | 2018 | 2455 | 0.020 |
Why?
|
Nitric Oxide | 1 | 1997 | 2146 | 0.020 |
Why?
|
Peroxidase | 2 | 2002 | 610 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2014 | 2362 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2010 | 549 | 0.020 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1176 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2012 | 1794 | 0.020 |
Why?
|
Mutation | 3 | 2015 | 30243 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4342 | 0.020 |
Why?
|
Alcoholism | 1 | 2017 | 1993 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 682 | 0.020 |
Why?
|
Germany | 1 | 2009 | 882 | 0.020 |
Why?
|
Vomiting | 1 | 2009 | 655 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 1997 | 1937 | 0.020 |
Why?
|
Point Mutation | 1 | 2011 | 1596 | 0.020 |
Why?
|
Endocrine Surgical Procedures | 1 | 2006 | 32 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2017 | 4526 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4586 | 0.020 |
Why?
|
Reproducibility of Results | 3 | 2014 | 20231 | 0.020 |
Why?
|
Clinical Competence | 1 | 2020 | 4841 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 937 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2020 | 14480 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 2964 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10494 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7471 | 0.010 |
Why?
|
Carcinoma, Ductal | 1 | 2004 | 97 | 0.010 |
Why?
|
Electrocardiography | 1 | 2017 | 6410 | 0.010 |
Why?
|
Models, Statistical | 1 | 2018 | 5103 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3794 | 0.010 |
Why?
|
Anticoagulants | 1 | 2019 | 4840 | 0.010 |
Why?
|
Glycodeoxycholic Acid | 2 | 1994 | 23 | 0.010 |
Why?
|
Patient Selection | 1 | 2015 | 4266 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 334 | 0.010 |
Why?
|
Image Enhancement | 1 | 2014 | 2894 | 0.010 |
Why?
|
Sex Factors | 2 | 2012 | 10647 | 0.010 |
Why?
|
Stomach | 1 | 2007 | 703 | 0.010 |
Why?
|
Mice | 2 | 2020 | 82045 | 0.010 |
Why?
|
Genetic Testing | 1 | 2015 | 3586 | 0.010 |
Why?
|
Nutritional Support | 1 | 2003 | 178 | 0.010 |
Why?
|
Random Allocation | 2 | 1998 | 2399 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2015 | 4642 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13324 | 0.010 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2011 | 2072 | 0.010 |
Why?
|
Cholecystokinin | 1 | 2001 | 115 | 0.010 |
Why?
|
Intestine, Small | 1 | 2007 | 1218 | 0.010 |
Why?
|
Trypsin | 1 | 2001 | 494 | 0.010 |
Why?
|
Pyloric Antrum | 1 | 2000 | 66 | 0.010 |
Why?
|
Technetium Compounds | 1 | 1999 | 15 | 0.010 |
Why?
|
Nicotinic Acids | 1 | 1999 | 33 | 0.010 |
Why?
|
Immunotherapy | 1 | 2015 | 4728 | 0.010 |
Why?
|
Sarcoma | 1 | 2010 | 1806 | 0.010 |
Why?
|
Acyltransferases | 1 | 2001 | 305 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 2001 | 1165 | 0.010 |
Why?
|
Complement Activation | 1 | 2001 | 448 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 6978 | 0.010 |
Why?
|
Microcirculation | 2 | 1994 | 1282 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2010 | 2544 | 0.010 |
Why?
|
Histocytochemistry | 1 | 1999 | 699 | 0.010 |
Why?
|
Pulmonary Edema | 1 | 2001 | 409 | 0.010 |
Why?
|
Endopeptidases | 1 | 2001 | 772 | 0.010 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2005 | 1252 | 0.010 |
Why?
|
Veins | 1 | 1999 | 767 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2001 | 2232 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10601 | 0.010 |
Why?
|
Internship and Residency | 1 | 2015 | 5952 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2010 | 4906 | 0.010 |
Why?
|
Gastrointestinal Agents | 1 | 1998 | 510 | 0.010 |
Why?
|
Duodenum | 1 | 1996 | 495 | 0.010 |
Why?
|
Isotonic Solutions | 1 | 1993 | 120 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18478 | 0.010 |
Why?
|
Spectrum Analysis | 1 | 1994 | 450 | 0.010 |
Why?
|
Saline Solution, Hypertonic | 1 | 1993 | 114 | 0.010 |
Why?
|
Melanoma | 1 | 2010 | 5740 | 0.010 |
Why?
|
Ascites | 1 | 1994 | 339 | 0.010 |
Why?
|
Up-Regulation | 1 | 2001 | 4138 | 0.010 |
Why?
|
Kidney | 1 | 2007 | 7064 | 0.010 |
Why?
|
Sodium Chloride | 1 | 1994 | 585 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 15638 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 1994 | 1379 | 0.010 |
Why?
|
Liver | 1 | 2007 | 7575 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1992 | 2087 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1993 | 1629 | 0.010 |
Why?
|
Injections | 1 | 1994 | 840 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 1993 | 1502 | 0.010 |
Why?
|
Treatment Failure | 1 | 1996 | 2656 | 0.010 |
Why?
|
Particle Size | 1 | 1993 | 1654 | 0.010 |
Why?
|
Fluid Therapy | 1 | 1993 | 585 | 0.000 |
Why?
|
Rats, Wistar | 1 | 1993 | 1891 | 0.000 |
Why?
|
Dogs | 1 | 1993 | 3847 | 0.000 |
Why?
|
Cost-Benefit Analysis | 1 | 2001 | 5532 | 0.000 |
Why?
|
Smoking | 1 | 2005 | 9099 | 0.000 |
Why?
|
Hemoglobins | 1 | 1994 | 1532 | 0.000 |
Why?
|
Health Care Costs | 1 | 1997 | 3265 | 0.000 |
Why?
|
Peptides | 1 | 1994 | 4368 | 0.000 |
Why?
|
Case-Control Studies | 1 | 1997 | 22293 | 0.000 |
Why?
|